Side-by-side comparison of AI visibility scores, market position, and capabilities
Oakland DLE lithium extraction technology ($318M total, $145M T. Rowe Price Series C); 5th gen 20x production rates with 1-acre = 10,000-acre evaporation pond efficiency and Great Salt Lake/Argentina deployments competing with SLB for lithium supply.
Lilac Solutions is an Oakland, California-based direct lithium extraction (DLE) technology company — backed with over $318 million in total funding including a $145 million Series C led by T. Rowe Price and Presidio Ventures — commercializing a proprietary ion exchange process that extracts lithium from brine resources with 70-98% efficiency using ceramic beads coated with nano-materials, achieving the same lithium output from a 1-acre system that conventional evaporation pond methods require 10,000 acres to produce. Founded in 2016 from CEO Dave Snydacker's PhD research at Northwestern University, Lilac was acquired new CEO Raef Sully (former CEO of Nutrien's $10 billion business unit) in 2024 to lead commercial scaling. In 2025, Lilac unveiled its fifth-generation DLE technology achieving 20x higher lithium production rates and 10,000 operational cycles before replacement — orders of magnitude better than competing technologies. Active projects include the Kachi project in Argentina (with Lake Resources), the Great Salt Lake project in Utah (targeting 3,000 tonnes per year by 2026), and the Neptune project in Germany. Lilac's manufacturing facility in Fernley, Nevada produces the ion exchange beads for commercial deployment. Investors include Breakthrough Energy Ventures.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.